Acutaas Chemicals Q1 FY27: 10 key numbers for July 2026

Results trigger: board meeting on July 24, 2026

Acutaas Chemicals Limited is set to hold a board meeting on July 24, 2026, to consider its audited financial results. The update is important for investors because it follows a year in which the company reported strong sequential momentum in quarterly revenue and profits, alongside ongoing capacity expansion. Ahead of the announcement window, the stock has been cited at different current market price (CMP) points in the available notes, including Rs 3,654.2 and Rs 3,695, and one reference to Rs 3,454.5. Market capitalisation is also shown at multiple levels, including Rs 29,917.37 crore and Rs 30,212 crore.

The company is part of the Pharmaceuticals and Biotechnology space, based on the sector tag included in the provided data. Investors tracking the release are also advised in the notes to verify numbers directly from NSE/BSE filings and sources such as Screener.in, as full quarterly financials for the ongoing cycle were described as not yet fully available on certain data partner feeds.

What investors are watching into Q1 FY27

The focus going into Q1 FY27 is shaped by three themes highlighted in the material: (1) the company’s rapid quarterly scale-up through FY2025-26, (2) margin expansion reflected in profit growth, and (3) capex plans for FY27.

In the lead-up commentary, Acutaas Chemicals was described as coming off “aggressive capacity expansion” and “strong sequential revenue growth” through the last fiscal year. The company’s own guidance mentioned in the notes points to a 25% CAGR revenue growth ambition, with management open to revisiting this if business potential exceeds expectations.

A separate guidance line in the provided information suggests EBITDA margins are expected to be maintained at FY26 levels, cited as approximately 42% quarterly and approximately 35% annual, supported by product mix and operating leverage. These are forward-looking statements within the material and not fresh reported results.

FY25-26 quarterly revenue build-up: Q1 to Q4

One narrative line summarises the revenue trajectory across FY2025-26, stating revenue rose from about Rs 207 crore in Q1 to Rs 432.75 crore by Q4. Supporting quarterly tables also show Q1 FY26 total revenue at Rs 207.24 crore and Q4 FY26 total revenue at Rs 432.75 crore.

The same quarterly comparison table shows Q4 FY26 total revenue at Rs 432.75 crore versus Rs 207.24 crore in Jun 2025, with year-on-year growth of 17.30% for the Jun 2025 quarter. It also shows a quarter-on-quarter decline for Jun 2025 versus Mar 2026, which is expected since Jun is Q1 and Mar is Q4.

In addition, another set of quarterly numbers presented as “Net Sales” lists Mar 2026 net sales at Rs 421.77 crore, and a separate summary line states Mar 2026 revenue at Rs 443.86 crore versus Dec 2025 revenue at Rs 397.88 crore. These differences indicate the data points are sourced from different summaries or definitions (for example, “revenue from operations” vs “net sales”), and should be cross-checked with the company’s filings.

Profit momentum: Q4 FY26 PAT, margins, and EPS trend

The notes state Acutaas Chemicals reported PAT of Rs 131.76 crore in Q4 FY2025-26, compared with Rs 62.5 crore in Q4 FY2024-25, indicating strong margin expansion. Another quarterly summary line pegs Mar 2026 net profit at Rs 134.28 crore versus Rs 106.22 crore in Dec 2025.

EPS trends are also visible in the quarterly tables. In one “Adjusted EPS” series, adjusted EPS rises to Rs 16.74 in Mar 2026 from Rs 13.63 in Dec 2025. In another quarterly EPS series, EPS for Mar 2026 is shown as Rs 16.09.

For Q1 FY26 (quarter ended Jun 2025), the highlights mention revenue from operations of Rs 2,072 million (which equals Rs 207.2 crore), EBITDA of Rs 509 million (Rs 50.9 crore), and PAT of Rs 440 million (Rs 44.0 crore), along with an export mix of 60% and domestic mix of 40%.

Balance sheet snapshot: net cash of about Rs 189 crore

A key balance sheet point in the provided notes is that Acutaas Chemicals maintained net cash of approximately Rs 189 crore at the end of Q4 FY2025-26. The same line item breaks this down into cash of Rs 215.5 crore against total borrowings of Rs 26.5 crore.

For investors, this matters because it frames FY27 capex and expansion plans against liquidity and leverage. It also reduces near-term financing risk, although the material does not provide a full cash flow statement.

FY26 full-year performance: lakh figures converted to crore

The material includes FY26 highlights in lakh, which translate into large year-on-year growth rates. On one set of FY26 numbers:

• Total Income: Rs 1,38,095.20 lakh (Rs 1,380.95 crore) in FY26 vs Rs 1,02,380.49 lakh (Rs 1,023.80 crore) in FY25, up 34.88%.
• Revenue from Operations: Rs 1,33,936.68 lakh (Rs 1,339.37 crore) in FY26 vs Rs 1,00,687.55 lakh (Rs 1,006.88 crore) in FY25, up 33.02%.
• PBT: Rs 48,272.57 lakh (Rs 482.73 crore) in FY26 vs Rs 21,616.30 lakh (Rs 216.16 crore) in FY25, up 123.32%.
• PAT: Rs 35,636.93 lakh (Rs 356.37 crore) in FY26 vs Rs 16,041.77 lakh (Rs 160.42 crore) in FY25, up 122.15%.

A separate “FY26 Standalone Financial Highlights” block shows:

• Total Income: Rs 1,36,967.05 lakh (Rs 1,369.67 crore) in FY26 vs Rs 1,00,817.02 lakh (Rs 1,008.17 crore) in FY25.
• Revenue from Operations: Rs 1,32,379.22 lakh (Rs 1,323.79 crore) in FY26 vs Rs 98,983.46 lakh (Rs 989.83 crore) in FY25.
• PAT: Rs 36,617.45 lakh (Rs 366.17 crore) in FY26 vs Rs 15,954.62 lakh (Rs 159.55 crore) in FY25.

Capex plan for FY27 and fundraising stance

The provided notes indicate FY27 capex plans around INR 100 crore, including INR 50 crore spillover from FY26 and around INR 40 crore maintenance capex, plus planned spending on a new R&D centre with exact figures pending finalisation. Another line in the material also frames FY27 planned capex around INR 90 crore (INR 50 crore spillover plus INR 40 crore maintenance), excluding R&D centre costs.

On fundraising, the notes explicitly say there is no mention of new fundraising through debt or equity in the provided transcripts for the near term. The commentary links this to management’s emphasis on “intelligent investment for growth” via R&D and capacity expansion.

Management commentary: confidence on FY27 growth

A management quote in the provided text is attributed to Naresh Patel, Executive Chairman and Managing Director. He stated that Q4 revenue from operations reached Rs 4,328 million (Rs 432.8 crore), up 40.3% year-on-year, alongside the company’s highest-ever PAT margin of 31.0%. He added that the company enters FY27 “from a position of strength” and expressed confidence of delivering 25% revenue growth in FY27.

This quote matters because it ties together the FY26 close with a clear growth target for FY27, which the market may evaluate against quarterly execution and margin stability.

Key numbers table to track before the result

Market impact: what the data implies so far

Ahead of the board meeting, the key market variables in the notes are the stock’s CMP around the mid-Rs 3,600 to Rs 3,700 range and market cap around Rs 30,000 crore, along with an indicated 12-month target band of Rs 3,732 to Rs 4,212. Valuation metrics in the material are inconsistent: one section lists P/E as “Not meaningful” while another shows P/E at 62.8. This reinforces the need to rely on the company’s latest filings and the precise EPS used in each calculation.

Operationally, the latest provided quarterly series suggests expense control and strong profit growth year-on-year, with Jun 2025 net income of Rs 44.29 crore versus Rs 13.95 crore in Jun 2024. But sequential comparisons between Jun 2025 and Mar 2026 are not directly indicative of trend because the March quarter includes Q4 seasonality effects and is also the year-end for reporting.

Conclusion: verified filings will set the narrative for Q1 FY27

Acutaas Chemicals goes into its July 24, 2026 board meeting after a FY26 close that included Q4 revenue from operations of about Rs 432.75 crore, PAT in the Rs 131.76 crore range, and net cash of roughly Rs 189 crore. The company’s FY27 plan highlights capex around INR 90 to 100 crore and a stated confidence in delivering 25% revenue growth.

The next concrete step is the company’s audited results consideration at the board meeting, after which investors can reconcile the differing revenue, profit, and valuation snapshots in circulation against the NSE/BSE disclosures.